Immune checkpoint inhibitor-induced bullous pemphigoid: evidence of dose dependency from two case studies
We report two patients with immune checkpoint inhibitor-induced bullous pemphigoid. The modification of immunotherapy dosing enabled the continuation of their anticancer treatment and facilitated the management of skin toxicity. These findings suggest that this immune-related adverse reaction may be dose-dependent, and adjusting the treatment regimen correctly may be key to its successful management.
Authors
- Vasiliki A. Nikolaou (ORCID: https://orcid.org/0000-0001-9340-9152)
- Christos Nikolaou (ORCID: https://orcid.org/0000-0001-6018-3564)
- Ioannis‐Alexios Koumprentziotis (ORCID: https://orcid.org/0000-0002-1156-7139)
- Evdoxia Panou (ORCID: https://orcid.org/0000-0002-8869-3889)
- Antonios Tsimpidakis (ORCID: https://orcid.org/0000-0003-0220-0762)
- Alexander Stratigos
Institutions
- National and Kapodistrian University of Athens (GR)
- Queen's Hospital (GB)
- Andreas Sygros Hospital (GR)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1093/ced/llaf140
- Citations
- 2
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.94